Case fatality and health care costs in HIV-infected patients: Evolution from 1992 to 2000 at Rouen University Hospital, France

International Journal of STD and AIDS

Volumn 15, Issue 10, 2004, Pages 679-684

  Basuyau, Florence ^a   Josset, V ^a   Merle, V ^a   Czernichow, P ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

Author keywords

AIDS; Economics; Fatal outcome; HAART; HIV

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; FRANCE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HEALTH CARE COSTS; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED;

EID: 4944232592     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462041944420     Document Type: Article

References (24)

1. Situation mondiale (2000). Journée Mondiale de lutte contre le SIDA. ONUSIDA. Address URL: [www.npcprev.sante.gouv.fr/sante-public/sida/13sid. pdf] (accessed 18 July 2001)
2. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH - Rapport 1999. Paris: Médecine - Sciences Flammarion, 1999
3. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997;336:1531-2
4. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997;11:101-5
5. Mocroft A, Johnson M, Phillips A. Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS 1996;10:1057-65
6. Jahnke N, Montessori V, Hogg R, et al. Impact of triple drug therapy on morbidity, mortality and cost. AIDS Revue 1999;1:57-60
7. Carosi G, Casari S, Palvarini L, et al. Health resource utilisation in the era of HAART: an Italian experience. Interscience Conference on Antimicrobial Agents Chemotherapy 1998;38:437
8. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999;13:963-9
9. Bozette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001;344:817-23
10. Le Pen C, Rozenbaum W, Downs A, et al. Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach. HIV Clin Trials 2001;2:136-45
11. Le Pen C, Rozenbaum W, Downs A, et al. A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996 [Article in French]. Thérapie 2002;57:27-33
12. Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS 1999;13:1115-22
13. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH - Mise à jour 2000. Paris: Médecine - Sciences Flammarion, 2000
14. Dariosecq JM, Girard PM. Infection à VIH - mémento thérapeutique. Paris: Doin, 1998
15. Wallace MR, Tasker SA, Shinohara YT, et al. The changing economics of HIV care. AIDS Patient Care STDS 2001;15:25-9
16. Wagner GJ, Remien RH, Carballo-Dieguez A, et al. Correlates of adherence to combination antiretroviral therapy among members of HIV-positive mixed status couples. AIDS Care 2002;14:105-9
17. Anonyme. Retour d'informations clinico-epidémiologiques. Paris: INSERM SC4. No 7, 2000
18. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000;356:291-7
19. Keiser P, Kvanli M.B, Turner D, et al. Protease inhibitor based therapy is associated with decreased HIV-related health care costs in men treated at a veterans administration hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:28-33
20. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001;344:824-31
21. The diabetes control and complications trial research group. Lifetime benefits and costs of intensive therapy as practised in the diabetes control and complications trial. JAMA 1996;276:1409-15
22. Moatti JP, Huard P. La juste évaluation des dépenses de santé. Pour la Science 1995;218:34-41
23. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:54-62
24. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94